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In the research, clinical, and wider community there is great interest in the use of stem
cells to reduce the progression, or indeed repair brain injury. Perinatal brain injury may
result from acute or chronic insults sustained during fetal development, during the process
of birth, or in the newborn period. The most readily identifiable outcome of perinatal brain
injury is cerebral palsy, however, this is just one consequence in a spectrum of mild
to severe neurological deficits. As we review, there are now clinical trials taking place
worldwide targeting cerebral palsy with stem cell therapies. It will likely be many years
before strong evidence-based results emerge from these trials. With such trials underway,
it is both appropriate and timely to address the physiological basis for the efficacy of
stem-like cells in preventing damage to, or regenerating, the newborn brain. Appropriate
experimental animal models are best placed to deliver this information. Cell availability,
the potential for immunological rejection, ethical, and logistical considerations, together
with the propensity for native cells to form teratomas, make it unlikely that embryonic
or fetal stem cells will be practical. Fortunately, these issues do not pertain to the use
of human amnion epithelial cells (hAECs), or umbilical cord blood (UCB) stem cells that
are readily and economically obtained from the placenta and umbilical cord discarded
at birth. These cells have the potential for transplantation to the newborn where brain
injury is diagnosed or even suspected. We will explore the novel characteristics of hAECs
and undifferentiated UCB cells, as well as UCB-derived endothelial progenitor cells (EPCs)
and mesenchymal stem cells (MSCs), and how immunomodulation and anti-inflammatory
properties are principal mechanisms of action that are common to these cells, and which
in turn may ameliorate the cerebral hypoxia and inflammation that are final pathways in
the pathogenesis of perinatal brain injury.
Keywords: Perinatal brain injury, stem cells, umbilical cord blood, amnion epithelial cells, cerebral palsy, clinical
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PERINATAL HYPOXIC-ISCHEMIC BRAIN INJURY
The neurological consequences of a severe hypoxic-ischemic
insult in the human brain at term birth are often dire, with resul-
tant hypoxic ischemic encephalopathy (HIE) a principal cause of
newborn death or permanent neurological disability, such as cere-
bral palsy (Johnston et al., 2011; Volpe, 2012). At risk neonates
include those who show signs of fetal distress prior to delivery,
have abnormal Apgar scores and require resuscitation at birth,
and show specific neurological abnormalities during the first 24 h
after delivery (Perlman, 2004). Although the underlying causes
and exact timing of brain injury in HIE infants are not always
known, there may be a principal severe intrapartum hypoxic-
ischemic insult at birth caused by placental abruption, umbilical
cord prolapse, or prolonged labor, but there may also be pre-
cipitating antenatal risk factors (such as preeclampsia, antenatal
bleeding, or intrauterine growth restriction) (Itoo et al., 2003;
Paolo, 2012).
The progression from hypoxic-ischemic insult through to
mass cell death within the perinatal brain has been extensively
examined and reviewed (Volpe, 2001a, 2012; Ferriero, 2004;
Gunn and Bennet, 2009). It may be described as a series of
phases beginning with the primary insult and energy depletion
through to subsequent reperfusion-induced cell death cascades.
Both human neuroimaging and experimental animal studies
demonstrate that damage to the developing brain evolves over
days and possibly weeks (Ferriero, 2004). In human infants,
neuronal cell death occurs in a series of chronological phases
after the original hypoxic-ischemic insult (Penrice and Nussey,
1992; Azzopardi and Edwards, 2010), a finding that has been
explored in greater detail in animal models of perinatal brain
injury (Berger and Garnier, 2000; Gunn and Bennet, 2009).
Primary neuronal death, in response to the insult, occurs due to
cellular hypoxia and exhaustion of high-energy stores (primary
energy failure). After return of cerebral perfusion and oxygena-
tion, the hypoxia-induced cytotoxic oedema and accumulation
of excitatory amino acids often resolves, together with recovery
of the depressed metabolic state of the brain. However, cere-
bral oxidative metabolism may deteriorate in the hours following
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an asphyxic period, and this phase may last for many days.
This secondary energy failure can be marked by the onset of
seizures, further oedema, accumulation of excitotoxins and cyto-
toxic inflammatory substances, failure of cerebral mitochondrial
activity and ultimately cell death (Gunn and Thoresen, 2006).
The duration and severity of this second, delayed wave of cerebral
compromise is closely associated with the degree of neurodevel-
opmental compromise at 1 year of age (Roth et al., 1992). By
analogy with events that occur in the adult brain after stroke or
traumatic brain injury, the damage arising during the “recovery”
phase is thought to be due to vascular paralysis, enhancement of
inflammatory processes, free radical formation, and breakdown
of the blood-brain barrier. Similarly in the developing brain,
we and others have shown that increased free radical formation
(Miller et al., 2005) and oedema (Bennet et al., 2007) occur in
the fetal sheep brain model of brief acute in utero asphyxia, sug-
gesting that the coupling of oxidative metabolism, oxygen supply,
and cerebral blood flow remain disturbed for some hours after
such events.
Presently, the only treatment available for babies diagnosed
with HIE soon after birth is to initiate hypothermia therapy.
Hypothermia as a therapeutic intervention has been extensively
investigated in human newborns (Gunn et al., 1998; Shankaran
et al., 2005; Simbruner et al., 2010; Higgins et al., 2011), where
hypothermia, after severe hypoxia-ischemia at birth, lowers the
incidence of death or major disability, resulting in significant
improvements in babies with moderate, but not severe, HIE
(Shankaran et al., 2005; Higgins et al., 2011). The principal mech-
anisms of hypothermia-induced neuroprotection are likely to
be multi-modal, with hypothermia functioning to reduce brain
perfusion and metabolism, decrease secondary energy failure
and oxidative stress leading to recovery of cerebral oxidative
metabolism, and a subsequent reduction in programmed cell
death (Katz et al., 2004). However, despite demonstrated efficacy,
when hypothermia is effectively applied 40–50% of infants will
still die or suffer significant neurologic disability following treat-
ment (Edwards et al., 2010; Massaro et al., 2013). Furthermore,
variations currently exist in the mode of administration of ther-
apeutic hypothermia (Harris et al., 2013) and to be effective,
hypothermia to treat HIE must commence within 6 h after birth,
indicative that the “window of opportunity” to reduce the pro-
gression of brain injury is limited to the immediate hours after the
insult (Vannucci and Perlman, 1997; Gunn et al., 2005; Higgins
et al., 2011). This is in contrast to the adult brain, where it has
been shown that treatment options extend over several hours post
insult and possibly days following a severe hypoxic-ischemic event
(Horn and Schlote, 1992). However, any therapeutic intervention
that exists to limit the degree of newborn brain injury is extremely
encouraging and provides a basis and the impetus to further
refine and develop new or adjunct neuroprotective treatments.
Therapies that can complement and provide additive benefit to
hypothermia must be considered where the principal aim is to
prevent or reduce the progression ofmass programmed cell death.
Alternatively, where a lack of perinatal brain injury diagnosis or
other logistical factors, such as availability of tertiary care, pre-
clude therapies within the hours that comprise the window of
opportunity, we must look toward alternative strategies such as
cell based therapies that could provide regenerative and repair
capacity within the young brain.
It should also be considered that while term hypoxic-ischemic
brain injury, and subsequent HIE, is a condition that is readily
identifiable and therefore amenable to treatment, there are other
significant chronic or acute causal factors that contribute to peri-
natal brain injury and neurodevelopmental deficits. Most notably,
in infants born preterm and in infants exposed to intrauter-
ine inflammation (chorioamnionitis), white matter brain injury,
which oftenmanifests as periventricular leukomalacia, is the most
common form of brain injury (Volpe, 2001b; Yoon et al., 2003).
In turn, periventricular white matter injury is the predominant
neuropathology observed in children with cerebral palsy (Leviton
and Paneth, 1990). Defining the time of onset and evolution
of white matter damage to the preterm brain is considerably
more challenging than delineating injury progression in response
to term hypoxia-ischemia. However, it is known that hypoxia-
ischemia and upregulation of inflammatory processes are final
common pathways contributing to periventricular white matter
brain injury in the newborn (Volpe, 2001b; Yoon et al., 2003;
Titomanlio et al., 2011).
STEM CELL THERAPY FOR PERINATAL BRAIN INJURY
Experimental clinical and animal studies have begun to elucidate
the utility of stem cell-based therapies to prevent or repair peri-
natal brain injury. Predominantly, these cells have been derived
either from neuronal embryonic or adult tissue (neural stem
cells), or from non-neural origin such as those isolated from bone
marrow and umbilical cord. Neural stem cells are self-renewing
and give rise to neurons, astrocytes, and oligodendrocytes.
Experimentally, these cells appeared to hold great promise for
neural repair after injury, including in perinatal hypoxic ischemic
brain injury (Felling et al., 2006; Daadi et al., 2013), however,
the therapeutic benefits of transplantation of neural stem cells
have not previously been convincingly shown (Andressen, 2013).
Neural stem cells are difficult to harvest, lack homogeneity, and
are found in very low numbers in the central nervous system
(Sommer and Rao, 2002). Stem cell therapies offer promising
treatment potential, with the exciting prospect that stem cells may
be able to act via a variety of diverse actions at different phases
of brain injury progression. However, in addition to considera-
tion of their efficacy, it is important to reflect on ethical concerns,
accessibility, and abundance of stem cells for clinical applications.
Accordingly, in this paper we will review stem cell-based thera-
pies using human amnion epithelial cells (hAECs) and umbilical
cord blood (UCB) derived cells; each with the potential to inter-
rupt both the evolutionary progression of perinatal brain injury
when the timing of the adverse insult is known, or to provide
regenerative capacity when the insult may have occurred in utero
and may, therefore, present as more advanced neuropathology.
Both hAECs and UCB can be easily and economically obtained
at human birth, from tissues that are otherwise discarded.
Accordingly, with the prospect that each of these cell lineages dis-
play independent protective and reparative properties, we raise
the intriguing possibility for autologous neuroprotective thera-
pies for the newborn brain in babies identified at-risk of brain
injury.
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HUMAN AMNION EPITHELIAL CELLS (hAECs)
Over the past decade there has been growing interest in the
reparative properties and potential uses of hAECs in treating
organ injury, including the rescue of adult neurodegenerative or
acute-onset brain disorders (Yang et al., 2010; Broughton et al.,
2013). The human amniotic membrane is formed from the epi-
blast on or around the eighth day after fertilization and before
gastrulation, and constitutes the inner layer of the amnion sur-
rounding the fetus (Akle et al., 1981). The human amniotic
membrane has key functions in pregnancy and embryonic devel-
opment; it has anti-inflammatory and immunological properties
that act to suppress the immune response against the fetus, has
multiple metabolic and transport functions and may contribute
to the onset and progression of uterine contractility (Mamede
et al., 2012). The cell populations within amniotic membrane
demonstrate pluripotent properties, reflecting the origin of this
membrane in utero, but also providing a rationale for clinical
applications of these cells (Parolini et al., 2008).
The innermost layer of the human amnion is 8–12μm thick
and consists of a single layer of homogeneous cuboidal epithe-
lial cells, so-called hAECs (Hebertson et al., 1986; Iwasaki et al.,
2003). hAECs display many characteristics of both embryonic
and pluripotent stem cells, with the potential to differentiate
into a range of cell types (Ilancheran et al., 2007; Parolini
et al., 2008). The amniotic fluid is also a source of cells with
similar characteristics to hAECs. The heterogenous population
of cells obtained from amniotic fluid at amniocentesis, have a
diverse capacity to differentiate and, as for hAECs, may thus
offer novel therapeutic potential (De Coppi et al., 2007). Both
amniotic fluid-derived stem cells and hAECs are positive for
CD117 (c-Kit) which is a transmembrane protein that functions
as a tyrosine kinase receptor—a receptor that is also present
on embryonic stem cells, primordial germ cells and somatic
stem cells including neural crest cells—however, amniotic fluid-
derived stem cells also appear distinct from hAECs on the basis
of differences in many cell surface markers and in gene expres-
sion patterns assessed by transcriptional profiling (Hipp and
Atala, 2006; Murphy et al., 2010). hAECs themselves have low
immunogenicity (Bailo et al., 2004) and indeed, rather than elic-
iting an immune response, they can reduce such a response
by inhibiting both innate and adaptive immune system cells
(Li et al., 2005). The role of hAECs in immunomodulation
appears multi-factorial, characterized by suppression of pro-
inflammatory cytokines (Solomon et al., 2001), regulation of
macrophage recruitment (Tan et al., 2013) and secretion of fac-
tors that inhibit the chemotactic activity of neutrophils and
macrophages (Li et al., 2005). These properties of hAECs, as sum-
marized in Figure 1, are very attractive when considering the
potential for cell-based therapies for treatment of brain injury.
Additionally amnion can be easily collected in a non-invasive
manner from the placenta which is discarded in ∼300,000
Australian births each year and hAECs can be isolated and stored
for later clinical use, without the need for expansion (Murphy
et al., 2010). In this respect, hAECs are readily available and their
use avoids the ethical issues that remain one of the major limi-
tations for the therapeutic use of embryonic stem cells (Yu et al.,
2009).
FIGURE 1 | Potential neuroprotective and neurorestorative
mechanisms of human amnion epithelial cells (hAECs). hAECs have
immunomodulatory properties which lead to a reduction of immune cell
infiltration into the brain, thus reducing inflammation. They secrete various
trophic and angiogenic factors which stimulate angiogenesis, neuronal
differentiation and survival, and decrease apoptotic cell death, thus leading
to improved functional outcomes.
PERINATAL HYPOXIC-ISCHEMIC BRAIN INJURY AND hAECs
Emerging evidence demonstrates the broad potential of hAECs
in the treatment of brain injury. Naïve hAECs express specific
neural marker genes, including neuro filament-M, myelin basic
protein, microtubule-associated protein 2, and glial fibrillary acid
protein (Mahmood et al., 2005), and cultured hAECs can be
directed toward a neural lineage, differentiating into neurons
and astrocytic cells (Sakuragawa et al., 1996; Ilancheran et al.,
2007; Toda et al., 2007). In culture, naïve, undifferentiated hAECs
are also reported to synthesize and secrete neurotransmitters
including catecholamines, acetylcholine, and neurotrophic fac-
tors (Sakuragawa et al., 1997; Elwan et al., 1998; Kakishita et al.,
2000).
The neural differentiation capacity and neurotrophic poten-
tial of hAECs has been examined in animal models of adult
brain pathology. In a rat experimental model of Parkinson’s dis-
ease [induced by 6-hydroxydopamine (6-OHDA) administration,
and causing multiple lesions], transplanted hAECs prevented the
death of dopaminergic neurons, mediated by the active secre-
tion of neurotrophic factors (Kakishita et al., 2000). In ischemic
stroke induced by middle cerebral artery occlusion in adults rats,
intra-cerebral injection of hAECs improved functional recovery
and decreased ischemic infarct volume, when compared with
non-hAEC treated rats (Liu et al., 2008). Although intra-cerebral
injections of such cells are unlikely to be promoted for treat-
ment of either adult or neonatal brain injury, it has recently been
shown that intravenous administration of amniotic fluid-derived
stem cells promotes significant motor and cognitive recovery in
rats subjected to ischemic stroke. Rats treated with amniotic fluid
stem cells demonstrated a significant decrease in brain infarct
volume and significantly increased endogenous cell proliferation
within proliferative zones, compared to post-stroke rats that did
not receive cell therapy (Tajiri et al., 2012). A recent literature
review by Broughton and colleagues provide an overview of
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the mechanisms that contribute to ischemic stroke injury and
explores the novel properties of hAECs and, to a lesser extent,
amniotic fluid- derived stem cells, and the properties that make
them appealing for stroke research (Broughton et al., 2013).
Research in this field is still in its relative infancy, but certainly
hAECs are considered a novel and promising cell-based therapy
for ischemic and inflammatory adult brain injury.
In developing preterm fetal sheep, we have recently pub-
lished data on the utility of hAECs to reduce organ injury and
to elucidate the mechanisms by which hAECs have their effect
(Vosdoganes et al., 2011; Hodges et al., 2012; Yawno et al.,
2013). In particular, we have been interested in novel thera-
pies to reduce or ameliorate inflammation-induced preterm lung
and brain injury. hAECs (180 million cells) delivered at 0, 6,
and 12 h relative to the time of inflammatory insult, mitigated
structural lung injury in preterm fetal sheep in utero and were
incorporated into lung tissue, albeit in relatively small num-
bers, where they differentiated into alveolar cells (Hodges et al.,
2012). In response to intrauterine inflammation induced by
intra-amniotic lipopolysaccharide, hAECs attenuated the fetal
inflammatory response by decreasing the localized increase in
pro-inflammatory cytokines within fetal lungs (Vosdoganes et al.,
2011). In turn, we have also reported that, by attenuating the
fetal inflammatory response, hAECs reduced fetal brain inflam-
mation and reduced gray and white matter preterm brain injury
(Yawno et al., 2013). The neuroprotective actions of hAECs in
the fetal brain were likely via anti-inflammatory effects, whereby
hAECs suppressed activated microglial cell upregulation within
the developing brain, which we showed to be correlated with
decreased cell death. A notable observation was that hAECs
were able to ameliorate lipopolysaccharide-induced periventric-
ular white matter injury, by preferentially protecting endogenous
oligodendrocytes (Yawno et al., 2013). Our understanding of the
principal actions of hAECs in the developing lung and brain have
been extended in mice models of adult lung disease, where hAECs
were shown to decrease macrophage infiltration in the lungs and
to promote the reparative M2 “alternatively activated” phenotype
of macrophages, with fewer M1 phenotype “classically activated”
pro-inflammatory macrophages (Tan et al., 2013). In related
experiments, hAECs have been shown to repair established adult
lung damage; however, these reparative benefits were found to be
dependent on the timing of hAEC administration. hAECs were
most beneficial at day 14 and not when administered earlier at
day 7, during a time of peak inflammation. This likely reflects the
evolution of the immune and inflammatory environment post-
insult and that hAECs are not only capable of preventing injury
but are also capable of repair once the injury is already established
(Vosdoganes et al., 2012). Further studies in models of adult lung
disease have demonstrated that the actions of hAECs were inde-
pendent of tissue engraftment and,most likely, were due to factors
released by hAECs rather than through direct effects of the hAECs
themselves (Tan et al., 2013). The fact that hAECs may be capable
of repairing established injury make them exciting and intriguing
candidates for repairing damage to the developing brain, which
is known to be mediated by inflammatory events and is often
only revealed once injury has occurred. Furthermore, the fact that
they can act via anti-inflammatory actions that are independent
of tissue engraftment provides a rationale for development of
therapies using the reparative factors, per se.
UMBILICAL CORD BLOOD STEM CELLS
UCB contains a rich and diverse mixture of stem and progenitor
cells that have the potential to generate a variety of cell types (Ali
and Bahbahani, 2010). In 1989, Broxmeyer, Gluckman, and col-
leagues demonstrated that UCB can be used in clinical settings
for stem cell transplantation (Broxmeyer et al., 1989; Gluckman
et al., 1989). Since then, UCB has been used to treat nearly 80
diseases with over 25,000 transplants worldwide. UCB represents
an abundant source of non-embryonic stem cells which are eas-
ily accessible with non-invasive collection of cells and no risk
to the donor. Such cells are more immature than their bone
marrow derived counterparts and hence display an impressive
proliferative potential (Tiwari et al., 2012; Tursky et al., 2012)
and have good viability after cells have been cryopreserved for
later use (Pipes and Ablin, 2006; Slatter et al., 2006). UCB stem
cells have high engraftment rates when used for replacement of
haematopoietic stem cell populations, are relatively tolerant of
HLAmismatches and thereby show low rates of graft-vs.-host dis-
ease, compared to bone marrow derived stem cells (Swijnenburg
et al., 2005). They are rarely contaminated with latent viruses
resulting in greater acceptance of UCB stem cells in comparison
to those from bone marrow. UCB has been widely used for the
treatment of various hematopoietic disorders (Kurtzberg, 1996;
Locatelli et al., 1998) but, of relevance to this review, they have
more recently been shown to induce regeneration in the central
nervous system (Harris and Rogers, 2007; Herranz et al., 2010).
UCB is rich in hemapoietic stem/progenitor cells, regula-
tory T-lymphocytes (Tregs), monocytes, mesenchymal stem cells
(MSCs), endothelial progenitor cells (EPCs), and stromal precur-
sor cells (Pimentel-Coelho et al., 2012) and, consequently, holds
promising potential for the treatment of neurological disorders.
Indeed, a recent pre-clinical study has shown that UCB transplan-
tation resulted in improved sensorimotor ability in a rat model
of hypoxic ischemic brain injury (Geissler et al., 2011). To our
knowledge, there are currently only a modest number of animal
studies that have examined the effects UCB transplantation fol-
lowing hypoxic-ischemic injury, predominantly in newborn rats.
These experiments using the Rice-Vannuci animal model (Rice
et al., 1981) have reported positive brain results following UCB
transplantation including decreased reactive gliosis (Wasielewski
et al., 2012), increased tissue repair, cognitive improvements
(de Paula et al., 2012), amelioration of injury-related effects in
the primary somatosensory cortex (Geissler et al., 2011) and
enhancement of endogenous neural stem cell proliferation via
Hedgehog signaling (Wang et al., 2013b). These pre-clinical tri-
als have not yet fully elucidated the mechanism underlying the
beneficial effects of UCB transplantation, and there are several
important questions that must be addressed before findings can
be translated to the bedside. Nevertheless, autologous intravenous
UCB transplantation has been shown to be safe and feasible in
young children with acquired neurological disorders (Buzanska
et al., 2006).
With respect to neonatal brain injury, UCB transplantation is
emerging as a promising therapeutic approach for treatment of
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hypoxic-ischemic brain injury and ischemic stroke (Wang et al.,
2012). There are now a number of human clinical trials taking
place to examine the potential therapeutic benefits of undifferen-
tiated cord blood cells for the treatment of established ischemic
brain injury and established cerebral palsy. For Table 1 we iden-
tified these trials through the ClinicalTrials.gov database using
the following search terms: UCB + newborn + ischemic brain
injury OR + cerebral palsy. Although some trials have now been
completed, there have been no peer-reviewed reports of them
published as yet. It is imperative that the timing of the administra-
tion of the UCB with respect to the time of the injury (if known)
is defined, as well as the optimal dose of UCB for transplantation.
Furthermore, the contribution and beneficial effects of the differ-
ent cell populations that are present in UCB need to be elucidated
in order to determine adequate therapies that could lead to fur-
ther improvement in neurological outcome, based on the clinical
scenario. We will further discuss two different cell types found
in cord blood, which independently show promise in pre-clinical
trials.
ENDOTHELIAL PROGENITOR CELLS (EPCs)
EPCs were originally identified as a population of stem cells in
human peripheral blood and characterized by their expression
of CD34, vascular endothelial receptor 2 (VEGFR-2), and CD133
markers (Asahara et al., 1997; Peichev et al., 2000). Subsequently,
EPCs have been isolated from other sources, such as bone mar-
row, fetal liver, and UCB. Although no specific markers are cur-
rently available for EPCs, the early functional angioblast, located
predominantly in the bone marrow are generally identified by
three surface markers (CD133, CD34, and VEGF-2), while circu-
lating EPCs (which have begun to mature into endothelial cells)
are usually characterized by expression of endothelial markers
such as VE-cadherin, endothelial nitric oxide synthase and von
Willebrand factor (Hristov and Weber, 2004). EPCs are stem
cells that are mobilized in response to acute hypoxia from bone
marrow and released into the circulation. Endogenous EPCs act
to maintain vascular integrity and homeostasis, and then, when
required, they are able to mediate the response to, and the repair
of, vascular injury. This reparative role is achieved by inducing
endothelial cell repair and regeneration, and by promoting tissue
neovascularization (Zhang et al., 2002). Experimental and human
studies show that EPCs participate in neovascularization pro-
cesses in ischemic organs, and hence their regulation could have
therapeutic applications in vascular diseases (Zampetaki et al.,
2008). In adult ischemic brain injury, such as occurs in stroke,
transplanted EPCs home to the ischemic injury core, and promote
cerebral neovascularization and neuron progenitor cell migration
and survival (Zhang et al., 2002; Fan et al., 2010).
EPCs, VASCULAR INTEGRITY AND REPAIR
Maintaining the integrity of the vascular endothelial monolayer
is extremely important, since it represents a barrier between the
blood and subendothelial matrix proteins, but also restricts the
infiltration of inflammatory cells, modulates vascular tone, and
controls vascular smooth muscle proliferation (Zampetaki et al.,
2008). The cerebrovascular system requires constant remodel-
ing and dynamic adaptation of the vascular network in response
to functional needs. In response to molecular cues that are ini-
tiated under conditions of hypoxia-ischemia, new blood vessel
formation in adults has traditionally been understood to result
primarily from angiogenesis, the process of local proliferation,
migration, and remodeling of endothelial cells from a mature
pre-existing endothelium (Red-Horse et al., 2007). This process
is dependent upon an array growth factors, matrix metallopro-
teinases, cytokines, and integrins. To date, over 20 endogenous
pro-angiogenic factors have been identified, including vascular
endothelial growth factor (VEGF), platelet derived growth factor
(PDGF), erythropoietin (EPO), and angiopoietin 1 and 2 (Ang-
1&2; Figure 2). Angiogeneis begins with an increase in vascular
permeability, followed by basement membrane and extracellu-
lar matrix degradation via matrix metalloproteinases (MMPs).
Endothelial cells then initiate migration along newly deposited
extracellular matrix tracts to form vessel sprouts. Finally, lumen-
containing vessels are formed and integrated into the circulation
(Red-Horse and Ferrara, 2006). From a therapeutic standpoint,
the vasculature of the central nervous system has attracted atten-
tion since a number of human ailments such as stroke, retinopa-
thy, cancer, and autoimmune disease are intimately associated
with vasculopathy. Stem cells, most notably EPCs, show great
potential as neurorestorative therapies as they target the basic
components of the neurovascular unit (endothelial cells, astro-
cytes, pericytes and smooth muscle cells, neural stem cells, oligo-
dendrocytes, and neurons) and the basic cellular elements that
form the basement membrane.
With the discovery of EPCs, it was demonstrated that neo-
vascularization after focal cerebral ischemia can also occur via
vasculogenesis—the de novo process of blood vessel formation by
differentiation and migration of EPCs in response to local cues
(Figure 2). EPCs migrate locally to injured tissue and participate
in neovacularization, regeneration of the injured endothelium,
or wound healing by providing a proliferative pool of cells with
the capacity to differentiate into mature vascular endothelial cells,
and by secreting pro-angiogenic growth factors (Zampetaki et al.,
2008). In this regard, EPCs are a potential tool for therapeu-
tic angiogenesis. VEGF, MMP-9, and EPO are involved in the
mobilization of EPCs into the circulation from the bone mar-
row (Zampetaki et al., 2008) and EPCs are recruited to new
sites of vascularization, using cues that resemble an inflamma-
tory response. The process of EPC homing to the site of injury
includes detachment from the bone marrow niche, rolling into
blood vessels, and traveling within the circulation. Once in the
vicinity of an injured vessel, EPCs interact with the damaged
endothelial monolayer in a similar way that leukocytes interact
with activated endothelial cells. Thus, adhesion molecules previ-
ously identified as being involved in the inflammatory response,
particularly leukocyte adhesion molecules (P-selectin, E-selectin,
β2-integrins) have now been identified as key regulators of EPC
homing (Zampetaki et al., 2008). Systemic administration of
umbilical cord blood-derived EPCs in adult mice results in sig-
nificant protection against hypoxic-ischemic brain injury, with
reduced infarct volume, decreased neutrophil infiltration, and
increased focal blood flow at 48 h after ischemia (Ohta et al.,
2006). Interestingly, this study also reported that circulating
EPC levels were inversely correlated with cerebral infarction, but
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FIGURE 2 | Recruitment of endothelial cells from pre-existing vessel
wall plays a critical role in the regulation of postnatal angiogenesis
and vasculogenesis. Mobilized bone marrow or umbilical cord
blood-derived EPCs with high proliferative capacity may have the potential
to migrate and incorporate into the injured tissue vascular bed.
Abbreviations: EC, endothelial cells; EPCs, endothelial progenitor cells;
VEGF, vascular endothelial growth factor; EPO, erythropoietin; MMPs,
matrix metalloproteinases, PDGF, platelet derived growth factor; Ang
1and2, angiopoietin 1 and 2.
positively correlated with regional blood flow in hypoperfused
areas of the brain after ischemia (Ohta et al., 2006), suggesting
that EPCs may be a functional predictor of the wellbeing of cere-
bral vasculature. Additionally, the level of circulating EPCs and
their migratory activity may serve as a marker for the risk of car-
diovascular diseases, and even as a predictor of vascular function
in many diseases (Vasa et al., 2001; Tepper et al., 2002; Baumhakel
et al., 2006; Werner and Nickenig, 2006a,b).
EPCs IN PREGNANCY AND THE FETUS
EPCs circulate at very low levels in adult human blood, and their
frequency and function may be secondarily impaired in response
to various complications (Vasa et al., 2001; Tepper et al., 2002;
Baumhakel et al., 2006; Werner and Nickenig, 2006a,b). In con-
trast, EPCs are enriched in term UCB, and cord blood EPCs
have been shown to proliferate faster and show enhanced ves-
sel forming ability in comparison to adult-derived EPCs (Yoder
et al., 2007; Au et al., 2008). Furthermore, the average num-
ber of cell progeny that can be derived from a single plate
of cord blood EPCs is reportedly 100-fold greater when com-
pared to those obtained from an adult, and can be serially re-
plated and expanded exponentially in long-term culture (Ingram
et al., 2004), suggesting that cord blood represents a rich source
of EPCs, with the potential for storage in large quantities for
clinical use.
In pregnancy, EPCs in the maternal circulation are present in
the second trimester (Gussin et al., 2002), and the number of cir-
culating EPCs increases gradually with gestational age (Sugawara
et al., 2005). A more recent study measured circulating EPCs
in cord blood at various stages of human gestation and found
that in infants born at 24–28 weeks of gestational age, the cord
blood yielded low levels of EPCs and high levels of MSCs, whereas
at 33–36 weeks gestation the cord blood yielded higher levels
of EPCs, equivalent to that found in term infants (Javed et al.,
2008). This was confirmed in another study investigating circu-
lating EPCs in preterm infants with bronchopulmonary dysplasia,
finding that EPC levels were relatively low below 32 weeks gesta-
tion, and increased as pregnancy progressed. Additionally, they
noted that extremely preterm infants with low levels of EPCs
had an increased risk of developing bronchopulmonary dysplasia
(Borghesi et al., 2009).
MESENCHYMAL STEM CELLS (MSCs)
MSCs are multi-potent cells with a strong capacity for self-
renewal, which can be isolated from a variety of tissues, such as
bone marrow, adipose tissue, umbilical cord, and UCB. MSCs
have the ability to differentiate into a variety of cell types, depend-
ing on cues from their microenvironment. MSCs have been
studied for use in neurologically related cell-based therapy in
adult experimental animal models and in clinical trials of human
brain disorders, such as Parkinson’s and Huntington’s disease,
traumatic brain injury, and stroke (Berry et al., 2006; Hermann
et al., 2010; Zilka et al., 2011; Kitada and Dezawa, 2012). MSCs
home to areas of insult, where they promote tissue repair via
secretion of soluble factors that enhance tissue regeneration, stim-
ulate proliferation, migration, and differentiation and survival of
endogenous local progenitor cells found in the microenviroment,
as well as by decreasing inflammatory and immune reactions and
apoptosis (Caplan and Dennis, 2006; Yi et al., 2012).
Transplanted MSCs augment host repair and tissue recovery,
primarily through trophic support that appears to be mediated by
direct and indirect actions. MSCs secrete both soluble (cytokines,
growth factors) and insoluble (extracellular matrix proteins) fac-
tors that promote neural cell survival and regeneration (neu-
rogenesis, angiogenesis, and synaptogenesis) through paracrine
signaling (Seo and Cho, 2012). Other protective actions that are
particular to the brain include remyelination (Akiyama et al.,
2012), and inhibition of apoptosis and inflammation (Caplan and
Dennis, 2006). The proposed neuroprotective effects of MSCs are
summarized in Figure 3.
PROTECTIVE MECHANISMS OF MSCs IN BRAIN INJURY
There is now solid preclinical data to demonstrate that MSC
transplantation promotes functional recovery following experi-
mental adult hypoxic ischemic brain injury or traumatic brain
injury (Parr et al., 2007). The mechanisms by which MSCs reg-
ulate neural recovery and repair in brain tissue is now being
extensively investigated, with a number of likely potential actions.
In culture, MSCs can be directed toward, and may spontaneously
generate, precursor and mature neuronal cells and cells of glial
(astrocytic) lineage (Woodbury et al., 2000; Deng et al., 2006).
When grafted into the lateral ventricle of the developing mouse
brain, MSCs migrate over significant distances and preferentially
differentiate into mature neurons and periventricular astrocytes
(Deng et al., 2006), suggesting that MSCs are primed toward
a neural fate. In addition to direct actions, MSCs secrete sol-
uble factors capable of stimulating proliferation of neural stem
cells in vitro, as well as increasing the expression of GFAP (a
marker of mature astrocytes) (Galindo et al., 2011). Further stud-
ies confirm that MSCs activate neural stem cells or progenitor
Frontiers in Neuroscience | Neuroendocrine Science October 2013 | Volume 7 | Article 194 | 8
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FIGURE 3 | Potential neuroprotective and neurorestorative effects of
mesenchymal stem cells (MSCs). The beneficial actions of MSCs are
mediated primarily by paracrine actions. MSCs secrete a number of
neurotrophic and angiogenic factors that promote neuronal growth and
differentiation, induce angiogenesis, neurogenesis and astroglial growth
and activation, they promote synaptogenesis thus enhancing synaptic
connections and axonal remyelination, decrease apoptosis, and decrease
macrophage infiltration, and microglia and T-lymphocyte activation.
cells (Munoz et al., 2005, 2012), and are capable of undergo-
ing expansion and differentiation into neurons, astrocytes, and
oligodendrocytes both in vitro (Reynolds et al., 1992) and after
transplantation in vivo (Alexanian et al., 2008; Kennea et al.,
2013). In response to MSC transplantation after brain ischemia,
there is an increase in new oligodendrocyte progenitor cells,
mature oligodendrocytes, and myelin formation in the ischemic
hemisphere (van Velthoven et al., 2011a). Transplantation of
human MSCs into the injury penumbra of monkeys, one week
following experimental cerebral ischemia, decreased apoptotic
cell death, and the lesion volume (Li et al., 2010; Xin et al., 2010).
In addition, Kim et al. (2010) showed that intravenous admin-
istration of human MSCs one day following traumatic brain
injury in rats improved functional recovery and enhanced host
cell survival by increasing pAkt and decreasing caspase-3 cleavage.
Intravenous delivery of MSCs one day following experimental
stroke in mice has also been shown to increase axon fiber density,
synaptogenesis, and myelination (Xin et al., 2010). An impor-
tant aspect of MSCs reparative role is the induction of trophic
factors in response to injury cues; these include brain derived
growth factor (BDNF), glial cell line-derived neurotrophic fac-
tor (GDNF), VEGF, fibroblast growth factor-2, and 7 (FGF-2,
FGF-7), fibronectin, heparin binding-epidermal growth factor-
like growth factor (HB-EGF), hepatocyte growth factor (HGF),
interleukin-6 (IL-6), leukemia inhibitory factor (LIF), monocyte
chemoattractant protein-1 (MCP-1), and PDGF (Li et al., 2002).
In addition to interacting directly with cells of the central ner-
vous system, MSCs communicate with immune cells and have
important immnosuppressive properties. MSCs suppress T- and
B-cell proliferation, inhibit natural killer cell function, andmodu-
late the secretory profile of microglia and macrophages (Le Blanc,
2003). Accordingly, treatment with MSCs is shown to decrease
T-lymphocyte activity thereby exerting an immunoregulatory
capacity (Fibbe et al., 2007; Gerdoni et al., 2007). In the
ischemic brain, MSCs transplantation has been demonstrated to
reduce the number of inflammatory cells (activated microglia
and macrophages) (Kim et al., 2008). By reducing microglial
expansion, MSC transplantation may reduce the inflammatory
response, thus favoring the generation and integration of new
neurons. MSC transplantation after acute traumatic brain injury
in rats results in modulation of the inflammatory response by
changing the expression of pro- and anti-inflammatory cytokines,
along with modulation of serum levels of chemokines (Galindo
et al., 2011). In a rat model of spinal cord injury, intravenously
transplanted MSCs decrease the level of the pro-inflammatory
cytokine IL-1β, reduced the number of activated microglia, and
increased the level of anti-inflammatory IL-10 (Seo and Cho,
2012). Additionally, a recent spinal cord injury study showed
that, similar to the actions described for hAECs, MSCs induced
a shift in macrophages from M1 pro-inflammatory phenotype,
to a M2 anti-inflammatory state, thereby promoting a protective
and regenerative response (Busch et al., 2011).
Finally, as was described for the actions of EPCs, a princi-
pal aspect of regeneration in the injured brain is angiogenesis
and vascular remodeling. In a rat model of stroke, intravenously
injected MSCs were shown to migrate selectively toward ischemic
areas of damaged brain to increase angiogenesis and improve
functional recovery (Chen and Keating, 2001; Li et al., 2002).
Evidence shows that these cells not only produce the appropri-
ate cytokine milieu necessary to promote an angiogenic response,
but they secrete pro-angiogenic factors such as VEGF, and regu-
late other trophic support for angiogenesis such as basic fibroblast
growth factor (bFGF), BMP-2, angiogenin and IL-6. Interestingly,
MSCs may also have the capacity to differentiate into endothelial
cells (Miranville et al., 2004; Rehman et al., 2004; Potapova et al.,
2007).
MSCs IN PREGNANCY AND THE FETUS
MSCs can be detected in fetal blood from between 7 and 13 weeks
gestation, with fetal MSCs being shown to have a characteristic
morphology and immunophenotype (Campagnoli et al., 2001).
Fetal MSCs are readily expandable in vitro and, as for adult bone
marrowMSCs, they have the capacity to differentiate into a num-
ber of mesenchymal lineages (Pittenger et al., 1999; Reyes and
Verfaillie, 2001; Devine, 2002). In the human fetus, circulating
MSCs and EPCs appear at different gestational ages; at preterm
24–28 weeks gestational age, there is a significantly higher concen-
tration of MSCs compared to EPCs within human UCB, which
then switches in term gestation UCB. Accordingly, the concen-
tration of MSCs decreases as human gestation proceeds to term,
leading to a near absence of MSCs in 37–40 weeks UCB (Javed
et al., 2008).
Despite the therapeutic potential that MSCs have demon-
strated in adult brain injury, presently, there are only a handful
of studies exploring the protective benefits of MSCs adminis-
tered to the newborn. Studies arising from The Netherlands
have guided the elucidation of the neuroprotective bene-
fits of MSCs in the newborn brain; van Velthoven et al.
(2011a) first demonstrated that bone-marrow derived MSCs
administered in response to neonatal acute hypoxic ischemic
brain damage improved functional outcome and reduced brain
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lesion volume. MSC-treated mice showed a decrease in the
number of proliferating microglia in the lesioned hemisphere,
decreased expression of proinflammatory cytokines in the
ischemic hemisphere, and increased differentiation of neurons
and oligodendrocytes (van Velthoven et al., 2011a,b). Most
recently this group demonstrated that, in this acute new-
born hypoxic-ischemic injury model, MSCs could be effec-
tively administered intra-nasally and maintain their functional
and structural neuroprotective benefits (Donega et al., 2013).
Similarly, it has been reported that MSCs derived from human
UCB and administered intra-cerebrally were able to ameliorate
neonatal rat hypoxic-ischemic brain injury, with MSC-treated
animals showing improved neurological score and differentiation
of MSCs into astrocytes but not neurons (Xia et al., 2010). In
a model of neonatal hyperoxic lung injury, intra-tracheal trans-
plantation of human UCB-derived MSCs attenuated lung injury
in neonatal rats, in a time-dependent manner, showing signifi-
cant protection in the early inflammatory phase (Chang et al.,
2013). To our knowledge, the only currently reported human
study evaluating the therapeutic potential of MSCs on brain
injury is a recent investigation in which umbilical cord MSCs
were administered to a 5-years-old girl with established cerebral
palsy. The patient was given 7 transplantations of MSCs over a
6-month period, and was followed for 28 months after the final
transplantation. Specifically, the study reported a reduction of
ambulation with tumble, with the patient being able to stand
up by herself, as well as other improvements such as enhanced
immunity, increased physical strength, and adjusted speech and
comprehension (Wang et al., 2013a).
CONCLUSIONS
Without question, stem cells therapies hold promise for the treat-
ment of a wide range of neurological disorders, including for
the treatment of perinatal brain injuries. Indeed the potential
and great hope placed in stem cells likely underlies the new
trend of “stem cell tourism.” But, as indicated in this review,
there remains many and varied unresolved or not yet addressed
important questions about the timing, appropriate cell types,
treatment strategies, and appropriate outcomes that must still be
addressed before such cells can be safely used in clinical trans-
lation studies. Have we yet adequately explored the long-term
safety of cord blood or hAECs administered to babies or chil-
dren? Over the past several years experimental animal studies
have provided essential insight into the efficacy and potential
mechanisms of stem cell therapies to protect and repair the adult
brain, yet there is still a relative lack of translational research
using experimental models of fetal and neonatal brain injury.
Despite this, and as shown in Table 1, there are a number of
clinical trials being conducted throughout the world investigat-
ing the effects of UCB on acquired brain injury in the newborn.
An in depth examination of the safety and efficacy of stem cells
in experimental models of fetal and neonatal brain injury is
urgently needed in order to advance stem cell therapy from the
laboratory to the clinic. More importantly, there is currently no
consensus regarding the optimal dose, mode of delivery and the
timing of stem cell treatment, which are likely to result in the
greatest improvement of neurological outcome, thus highlight-
ing the importance of future pre-clinical studies will well-defined
outcomes.
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